From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Powerful New Prognostic Markers in Patients with Chest Pain

Myeloperoxidase and glutathione peroxidase 1 levels were independent predictors of adverse coronary events.

In recent years, new blood tests, such as those for C-reactive protein (CRP) and homocysteine, that predict the presence of coronary artery disease and coronary outcomes have entered clinical practice. In 2 studies, researchers have evaluated 2 new markers, with impressive results.

A team from Cleveland Clinic evaluated blood levels of a marker of activated leukocytes, myeloperoxidase (MP), in 604 sequential patients with chest pain in an emergency department. MP is a leukocyte enzyme that concentrates in ruptured plaques. After adjustment for other risk factors, elevated levels of MP were highly predictive of adverse coronary outcomes (myocardial infarction, revascularization, or death) within 30 days or 6 months. MP level was a more accurate predictor than were levels of CRP or troponin T; MP level also was a powerful predictor of short-term adverse outcomes among patients with persistently negative troponin T tests, whereas CRP was not.

A German team evaluated another marker, glutathione peroxidase 1 (GP1), which is a powerful antioxidant that is present in atherosclerotic plaques. A total of 636 patients with suspected coronary artery disease were followed for a median of 4.7 years. Higher baseline levels of GP1 were associated with lower rates of cardiovascular events, even after adjustment for other risk factors (hazard ratio, 0.29 for highest vs. lowest GP1 quartiles). Blood markers that were associated significantly with adverse outcomes were high levels of interleukin-6, high levels of homocysteine, and low levels of GP1. Although CRP level had independent predictive power, it was not as strong a predictor as the other factors.

Comment: These findings indicate dynamic movement in the field of rapid diagnostic markers for coronary risk. Although none of these blood tests was compared directly to coronary imaging studies, these results suggest that simple screening blood tests can provide as much predictive information as can more expensive or invasive studies, such as exercise testing, computed tomography, or magnetic resonance imaging.

— Anthony L. Komaroff, MD

Published in Journal Watch General Medicine November 25, 2003

Citation(s):

Brennan M-L et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003 Oct 23; 349:1595-604.

Blankenberg S et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 2003 Oct 23; 349:1605-13.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Related Content

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2003. Massachusetts Medical Society. All rights reserved.